Navigation Links
GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
Date:12/11/2009

LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ -- In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

The study included 296 women with a type of breast cancer known as HER2-positive disease, characterized by an overexpression of the HER2 protein in the cancer cells. Patients enrolled in the study experienced recurrence of breast cancer despite a median of three prior trastuzumab-based therapies. The data presented at the San Antonio congress showed that patients overcame resistance to trastuzumab with the introduction of the lapatinib-trastuzumab combination.

"The clinical benefits brought forth by the lapatinib and trastuzumab combination are quite compelling and lead me to believe the agents may be acting together to form a sort of 'dual blockade' to obstruct the HER2 pathway necessary for the tumor to thrive," said primary investigator, Kimberly Blackwell, M.D., Duke University Medical Center.

Patients in the study were randomized to receive single agent lapatinib (1500 mg/daily) or a combination of lapatinib (1000 mg p.o. daily) plus trastuzumab (2 mg/kg). For those patients treated with monotherapy lapatinib, cross-over to the combination was allowed if the disease progressed after at least four weeks of therapy. Final analysis showed clinical activity for lapatinib in the control arm. Women treated with monotherapy lapatinib experienced a median overall survival of 9.5 months compared with 14 months when treated with the combination (median HR: 0.74, p=0.026).

"It's possible that, by lapatinib working inside the c
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
2. Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
3. DecisionView Launches StudyOptimizer(TM) 4
4. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
5. OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
8. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
9. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
10. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... NEW YORK , June 3, 2015 ... grow at a CAGR of 10.1% from 2014 to ... market is driven by factors, such as the rising ... and growing technology advancements. However, factors such as lack ... the growth of this market. In ...
(Date:6/3/2015)... 3, 2015  Diomics today announced that Stephen ... has joined the company,s board of directors, effective immediately. ... Project and Clinical Professor at the Lyndon B. Johnson ... at Austin. "Steve brings an incredible ... years as a member of CIA,s clandestine service, including ...
(Date:6/3/2015)... DUBLIN , June 3, 2015  Actavis plc (NYSE: ... that Brent Saunders , CEO and President of Actavis, ... at the Goldman Sachs 36th Annual Global Healthcare Conference in ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO The presentation ... a.m. Pacific Time at the Terranea Resort, Rancho ...
Breaking Medicine Technology:Dermatology Treatment Devices Market by Type, by Application - Global Forecast to 2019 2Dermatology Treatment Devices Market by Type, by Application - Global Forecast to 2019 3Former CIA Clandestine Service Senior Official Stephen B. Slick joins Diomics Board of Directors 2Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2
... Serina Therapeutics, Inc. President and CEO Randall Moreadith, MD, PhD, ... financing round to advance its lead oncology candidate SER-203 into ... "We are pleased to report to our existing and ... launched in late 2010. This is a very significant milestone ...
... (Nasdaq: ENDP ) today announced that Alan Levin, ... corporate overview at the Goldman Sachs Global Healthcare Conference on ... will be held at the Terranea Resort in Rancho Palos ... of the presentation will be available on the company,s website ...
Cached Medicine Technology:Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
(Date:6/3/2015)... The Bay Pines VA Healthcare System (VAHCS) will hold ... (VHA) National Women Veterans Campaign on June 12. The event ... the first floor of the C.W. Bill Young VA Medical ... and their families, Veteran Service Organizations, other stakeholders, and the ... event flyer, click here. , The event will showcase various ...
(Date:6/3/2015)... 2015 blingsting announces their new product, ... glove compartment or can be strapped onto a visor. ... a pointed tip that will allow the user to ... that can cut through a seatbelt or carseat strap ... include:, ,         Easily break a window or ...
(Date:6/3/2015)... June 03, 2015 As of 2014, ... information systems marketplace. Its share in the Asian market ... player. The market in this country is forecast to ... 2019, while the Asian market is expected to grow ... period. , Some of key factors encouraging growth of ...
(Date:6/3/2015)... Accountable care organizations (ACOs) are increasingly ... initial worries that these product types were too similar ... indicate that product-based ACOs will continue to grow in ... the June issue of Atlantic Information Services, Inc.’s (AIS) ... anecdotally that the backlash from HMOs seems to be ...
(Date:6/3/2015)... June 03, 2015 A recent ... precautions on product labels underscores the importance of ... to the American Society for Dermatologic Surgery Association. ... new warnings about the risks for serious injury ... While product labels already include information about risks, ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:blingsting Announces All New Car Safety Tool The Glammer 2Health News:Asian Pharmacy Information Systems Market to Grow at a 8.3% CAGR through 2019, Says MicroMarketMonitor in its New Report Available at MarketPublishers.com 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 3Health News:ASDSA Supports FDA Fillers Directive 2Health News:ASDSA Supports FDA Fillers Directive 3Health News:ASDSA Supports FDA Fillers Directive 4
... U.S. News Media Group and the National Committee ... edition of America,s Best Health Insurance Plans on ... open-enrollment season, when Americans nationwide prepare to select their ... provides consumers with comprehensive rankings and important detailed information ...
... Nov. 12 Bausch & Lomb, the global eye health ... its Board of Directors. , Mr. Hassan was chairman ... by Merck & Co., Inc. on November 3. Before joining ... as chairman and CEO (from 2001 to 2003) of Pharmacia ...
... her bout with H1N1, made all the worse by chronic asthma ... been following the news about the H1N1 swine flu with some ... And from the many hours talking with infectious-disease specialists, I knew ... might be another flu pandemic, but when . , The ...
... ... holiday recipe for Holly Jolly Biscotti, which showcases the peak-season flavors of Texas citrus and ... to promote a good-for-you diet throughout the holidays not just for yourself, but everyone on ... Dallas, ...
... ... of Fresh Throne are the quickest way to keep any bathroom fit for royalty. During product ... ... brand new, all natural spray shield aimed at protecting against horrible bathroom odors. Just a ...
... 11 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a ... development of drug products that are delivered to and ... delivery technologies, and on the development of its immune ... agreement for Oxoferin(TM), its topical wound healing agent, and ...
Cached Medicine News:Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 2Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 3Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 4Health News:Fred Hassan Joins Bausch & Lomb Board of Directors 2Health News:My 10-Day Ordeal With the Swine Flu 2Health News:My 10-Day Ordeal With the Swine Flu 3Health News:My 10-Day Ordeal With the Swine Flu 4Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 3Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 4Health News:Fresh Throne Eco-Friendly Bathroom Spray Celebrates Launch by Donating to Salvation Army 2Health News:Nuvo research provides WF10 licensing and development update 2Health News:Nuvo research provides WF10 licensing and development update 3Health News:Nuvo research provides WF10 licensing and development update 4Health News:Nuvo research provides WF10 licensing and development update 5
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... 70% USP and 10% Acetone Alcohol Prep ... antiseptic, anti-infective prior to administering injections. Acetone ... and fats from the skin. They are ... to contain a consistent amount of alcohol ...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: